Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria - Jiang, Haiyue; Yang, Yaqing; Tang, Zihan; Pan, Haoyu; Liu, Honglei; Cheng, Xiaobing; Su, Yutong; Ye, Junna; Hu, Qiongyi; Meng, Jianfen; Chi, Huihui; Zhou, Zhuochao; et al. (Scientific reports, 2025)
Keywords: 631/250; 631/250/38; Adult; Antibodies; Antibodies, Anticardiolipin - blood; Antibodies, Anticardiolipin - immunology; Antibodies, Antiphospholipid - blood; Antibodies, Antiphospholipid - immunology; Antiphospholipid antibodies; Antiphospholipid autoantibodies; Antiphospholipid syndrome; Antiphospholipid Syndrome - blood; Antiphospholipid Syndrome - classification; Antiphospholipid Syndrome - diagnosis; Antiphospholipid Syndrome - immunology; Autoimmune diseases; beta 2-Glycoprotein I - immunology; Cardiolipin; Case-Control Studies; Chemiluminescence; Chemiluminescence assay; Classification; Clinical significance; Disease; Efficiency; Enzyme-Linked Immunosorbent Assay; Enzymes; Female; Glycoprotein I; Glycoproteins; Hospitals; Humanities and Social Sciences; Humans; IgM; Immunoassay; Immunoglobulin G; Immunoglobulin G - blood; Immunoglobulin G - immunology; Immunoglobulin M; Immunoglobulin M - blood; Laboratories; Luminescent Measurements - methods; Lupus; Male; Middle Aged; Morbidity; multidisciplinary; Pregnancy; Risk assessment; Risk factors; ROC Curve; Science; Science (multidisciplinary); Thrombocytopenia; Thromboembolism; Thrombosis; Antiphospholipid autoantibodies; Chemiluminescence assay; IgM; Enzyme-linked immunosorbent assay; Antiphospholipid syndrome